Compare · COEP vs RVMD
COEP vs RVMD
Side-by-side comparison of Coeptis Therapeutics Holdings Inc. (COEP) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COEP and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $27.92B, about 273.6x COEP ($102.1M).
- Over the past year, COEP is up 101.4% and RVMD is up 242.7% - RVMD leads by 141.3 points.
- Both names hit the wire about 22 times in the past 4 weeks.
- RVMD has more recent analyst coverage (25 ratings vs 0 for COEP).
- Company
- Coeptis Therapeutics Holdings Inc.
- Revolution Medicines Inc.
- Price
- $16.27+0.81%
- $139.60-3.20%
- Market cap
- $102.1M
- $27.92B
- 1M return
- +46.05%
- +41.57%
- 1Y return
- +101.36%
- +242.66%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2020
- News (4w)
- 22
- 22
- Recent ratings
- 0
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest COEP
- Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form 4 filed by Director Sohn Adam Craig
- SEC Form 4 filed by Chief Marketing Officer Schadel Christopher Ryan
- SEC Form 4 filed by Director Fuerst Bryan Eric
- SEC Form 4 filed by Co-Chief Executive Officer Halabu David Elias
- SEC Form 4 filed by Director Cooper Kenneth Lyle
- SEC Form 4 filed by Chief Financial Officer Cogley Brian
- Co-Chief Executive Officer Burke Michelle Ellen was granted 16,447 shares (SEC Form 4)
- SEC Form 3 filed by new insider Sohn Adam Craig
Latest RVMD
- Officer Mancini Anthony exercised 3,120 shares at a strike of $33.62 and sold $413,129 worth of shares (3,120 units at $132.41) as part of a pre-agreed trading plan (SEC Form 4)
- Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026
- SEC Form DEFA14A filed by Revolution Medicines Inc.
- SEC Form DEF 14A filed by Revolution Medicines Inc.
- Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting
- Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting
- Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
- SEC Form 4 filed by Goldsmith Mark A
- Revolution Medicines Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional Shares